Guide Swap enables genome-scale pooled CRISPR-Cas9 screening in human primary cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30297964.
- Also identified by DOI 10.1038/s41592-018-0149-1.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
CRISPR-Cas9 screening allows genome-wide interrogation of gene function. Currently, to achieve the high and uniform Cas9 expression desirable for screening, one needs to engineer stable and clonal Cas9-expressing cells-an approach that is not applicable in human primary cells. Guide Swap permits genome-scale pooled CRISPR-Cas9 screening in human primary cells by exploiting the unexpected finding that editing by lentivirally delivered, targeted guide RNAs (gRNAs) occurs efficiently when Cas9 is introduced in complex with nontargeting gRNA. We validated Guide Swap in depletion and enrichment screens in CD4<sup>+</sup> T cells. Next, we implemented Guide Swap in a model of ex vivo hematopoiesis, and identified known and previously unknown regulators of CD34<sup>+</sup> hematopoietic stem and progenitor cell (HSPC) expansion. We anticipate that this platform will be broadly applicable to other challenging cell types, and thus will enable discovery in previously inaccessible but biologically relevant human primary cell systems.
Medical subject headings
- CD8-Positive T-Lymphocytes
- CRISPR-Associated Protein 9
- CRISPR-Cas Systems
- Gene Editing
- Genome, Human
- Hematopoietic Stem Cells
- RNA, Guide, CRISPR-Cas Systems